Table 2.
Main Pharmacokinetic Parameters of FA After Oral Administration in Rats (n=6)
| FA | FA-SMEDDS | |
|---|---|---|
| AUC0-t (h·μg/mL) | 82.86 ± 26.59 | 143.48 ± 39.75** |
| Cmax (μg/mL) | 73.20 ± 14.22 | 83.45 ± 26.67 |
| Tmax (h) | 0.58 ± 0.20 | 0.61 ± 0.33 |
| T1/2 (h) | 1.39 ± 0.36 | 2.10 ± 0.76* |
| MRT0-t (h) | 1.40 ± 0.34 | 1.84 ± 0.38** |
| V/F (× 106 L/kg) | 1.22 ± 0.58 | 3.14 ± 1.10** |
| CL/F (× 105 L/h/kg) | 2.50 ± 0.86 | 1.42 ± 0.31** |
| Fr (%) | — | 185.96 ± 74.44 |
Notes: Results suggest that SMEDDS improved the oral bioavailability of FA by slowing its elimination. *P < 0.05; **P < 0.01, vs FA group.
Abbreviations: AUC, Area under the concentration–time curve; Cmax, Peak concentration; Tmax, Time to the Cmax; T1/2, Biological half-life; MRT, Mean residence time; Vz/F, Apparent volume of distribution/bioavailability; CL/F, Clearance/bioavailability; Fr, Relative bioavailability.